Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions

Psychiatry Research

Volumn 177, Issue 1-2, 2010, Pages 255-260

  Iasevoli, Felice ^a   Fiore, Germano ^a   Cicale, Maria ^a   Muscettola, Giovanni ^a   de Bartolomeis, Andrea ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

D2; Dopamine; Glutamate; Homer; Immediate early genes; In situ hybridisation histochemistry; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MEMBRANE PROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PROTEIN HOMER 1A; PROTEIN YOTIAO; RISPERIDONE; SCAFFOLD PROTEIN; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; GENE INDUCTION; HISTOCHEMISTRY; IMMEDIATE EARLY GENE; IN SITU HYBRIDIZATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE ANALYSIS; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN MAPPING; CARRIER PROTEINS; CORPUS STRIATUM; GENE EXPRESSION REGULATION; HALOPERIDOL; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; RNA, MESSENGER; SULPIRIDE;

EID: 77952093931     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.02.009     Document Type: Article

References (49)

1. Ambesi-Impiombato A., D'Urso G., Muscettola G., de Bartolomeis A. Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Research Protocols 2003, 11:189-196.
2. Ambesi-Impiombato A., Panariello F., Dell'aversano C., Tomasetti C., Muscettola G., de Bartolomeis A. Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse 2007, 61:429-439.
3. Assie M.B., Dominguez H., Consul-Denjean N., Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn-Schmiedebergs Archives of Pharmacology 2006, 373:441-450.
4. Bai O., Zhang H., Li X.M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Research 2004, 1010:81-86.
5. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R., Flanagan R.J., Ell P.J., Pilowsky L.S. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. American Journal of Psychiatry 2003, 160:1413-1420.
6. de Bartolomeis A., Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacology Bulletin 2003, 37:51-83.
7. de Bartolomeis A., Aloj L., Ambesi-Impiombato A., Bravi D., Caraco C., Muscettola G., Barone P. Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Molecular Brain Research 2002, 98:124-129.
8. Feliciello A., Cardone L., Garbi C., Ginsberg M.D., Varrone S., Rubin C.S., Avvedimento E.V., Gottesman M.E. Yotiao protein, a ligand for the NMDA receptor, binds and targets cAMP-dependent protein kinase II(1). FEBS Letters 1999, 464:174-178.
9. Fisher R.S., Levine M.S., Sibley D.R., Ariano M.A. D2 dopamine receptor protein location: Golgi impregnation-gold toned and ultrastructural analysis of the rat neostriatum. Journal of Neuroscience Research 1994, 38:551-564.
10. Fujimura M., Hashimoto K., Yamagami K. The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison with haloperidol, clozapine and risperidone. Life Science 2000, 67:2865-2872.
11. Fumagalli F., Frasca A., Racagni G., Riva M.A. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Molecular Pharmacology 2008, 73:1484-1490.
12. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. Journal of Neuroscience 1987, 7:3915-3934.
13. Ishibashi T., Tagashira R., Nakamura M., Noguchi H., Ohno Y. Effects of perospirone, a novel 5-HT2 and D2 receptor antagonist, on Fos protein expression in the rat forebrain. Pharmacology Biochemistry Behavior 1999, 63:535-541.
14. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. Journal of Pharmacology and Experimental Therapeutics 2003, 305:625-631.
15. Konradi C., Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology & Therapeutics 2003, 97:153-179.
16. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
17. Kristiansen L.V., Beneyto M., Haroutunian V., Meador-Woodruff J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Molecular Psychiatry 2006, 11(737-747):705.
18. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clinical Therapeutics 2005, 27:S16-S24. Suppl A.
19. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361:1581-1589.
20. Leveque J.C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.M., Coyle J.T., Huganir R.L., Heckers S., Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. Journal of Neuroscience 2000, 20:4011-4020.
21. Lin J.W., Wyszynski M., Madhavan R., Sealock R., Kim J.U., Sheng M. Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. Journal of Neuroscience 1998, 18:2017-2027.
22. Manschreck T.C., Boshes R.A. The CATIE schizophrenia trial: results, impact, controversy. Harvard Review of Psychiatry 2007, 15:245-258.
23. Meisenzahl E.M., Schmitt G.J., Scheuerecker J., Moller H.J. The role of dopamine for the pathophysiology of schizophrenia. International Review of Psychiatry 2007, 19:337-345.
24. Miyamoto A., Yamamoto T., Ohno M., Watanabe S., Tanaka H., Morimoto S., Shoyama Y. Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Research 1996, 710:234-240.
25. Nakahara T., Kuroki T., Hashimoto K., Hondo H., Tsutsumi T., Motomura K., Ueki H., Hirano M., Uchimura H. Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain. NeuroReport 2000, 11:551-555.
26. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., Kapur S. Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophrenia Research 2008, 105:224-235.
27. O'Connor J.A., Muly E.C., Arnold S.E., Hemby S.E. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs. Schizophrenia Research 2007, 90:28-40.
28. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 1999, 33:523-533.
29. Ozaki T., Mui K., Yamagami S. Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression. European Journal of Pharmacology 1999, 369:133-143.
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press Inc, Sydney, Australia.
31. Polese D., de Serpis A.A., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 2002, 27:906-913.
32. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007, 32:1715-1726.
33. Rosa-Neto P., Doudet D.J., Cumming P. Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. Neuroimage 2004, 22:1076-1083.
34. Russell V.A., Allin R., Lamm M.C., Taljaard J.J. Regional distribution of monoamines and dopamine D1- and D2-receptors in the striatum of the rat. Neurochemistry Research 1992, 17:387-395.
35. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology (Berl) 1998, 135:182-193.
36. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Molecular Psychiatry 1998, 3:123-134.
37. Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochemistry International 1996, 29:435-442.
38. Semba J., Sakai M.W., Suhara T., Akanuma N. Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization. Neurochemistry International 1999, 34:269-277.
39. Shiraishi-Yamaguchi Y., Furuichi T. The Homer family proteins. Genome Biology 2007, 8:206.
40. Szele F.G., Artymyshyn R., Molinoff P.B., Chesselet M.F. Heterogeneous distribution of dopamine D2 receptor mRNA in the rat striatum: a quantitative analysis with in situ hybridization histochemistry. Anatomical Record 1991, 231:548-558.
41. Tappe A., Kuner R. Regulation of motor performance and striatal function by synaptic scaffolding proteins of the Homer1 family. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:774-779.
42. Toro C., Deakin J.F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophrenia Research 2005, 80:323-330.
43. Tu H., Tang T.S., Wang Z., Bezprozvanny I. Association of type 1 inositol 1, 4, 5-trisphosphate receptor with AKAP9 (Yotiao) and protein kinase A. Journal of Biological Chemistry 2004, 279:19375-19382.
44. Voorn P., Vanderschuren L.J., Groenewegen H.J., Robbins T.W., Pennartz C.M. Putting a spin on the dorsal-ventral divide of the striatum. Trends in Neuroscience 2004, 27:468-474.
45. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
46. Wan W., Ennulat D.J., Cohen B.M. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Research 1995, 688:95-104.
47. Wang X., Zhong P., Yan Z. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. Journal of Neuroscience 2002, 22:9185-9193.
48. Westphal R.S., Tavalin S.J., Lin J.W., Alto N.M., Fraser I.D., Langeberg L.K., Sheng M., Scott J.D. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science 1999, 285:93-96.
49. Willuhn I., Sun W., Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. European Journal of Neuroscience 2003, 17:1053-1066.